BRAF inhibition for colon cancer

Some patients being treated for stage three colon cancer could avoid the use of chemotherapy and be spared toxicities such as neuropathy: according to a study in which ctDNA liquid biopsy monitoring f

An interview with: Elena Elez MD PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain CHICAGO, USA—Adding the BRAF inhibitor encorafenib (partnered with EGFR-inhibitor cetuximab) to standa